Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5604118 | International Journal of Cardiology | 2017 | 31 Pages |
Abstract
Findings of this contemporary European ACS-cohort showed markedly lower cardiac event rates than TRITON-TIMI 38 and no significant difference in 2-year QALYs between prasugrel and clopidogrel-treated patients. At current drug prices, clopidogrel use resulted in an economically dominant treatment strategy in Western European patients.
Keywords
dNKICERIPTWMACEPCIBMSDAPTIQRNSTEMIACSDRGDrug Eluting Stent (DES)GermanyMyocardial infarctionCost-effectivenessDESdrug eluting stentbare metal stentNon-ST-elevation myocardial infarctionBARCcoronary artery diseaseGERBleeding Academic Research ConsortiumDenmarkdual antiplatelet therapyAcute coronary syndrome (ACS)Acute coronary syndromeCADconfidence intervalinter-quartile rangepercutaneous coronary interventionhazard ratioincremental cost effectiveness ratioPrasugrelclopidogrelDiagnosis related groupsEUREuro
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Bastian Wein, Michael Coslovsky, Reza Jabbari, Søren Galatius, Matthias Pfisterer, Christoph Kaiser,